BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Bristol-Myers Squibb (BMS) and Celgene have entered into a definitive merger agreement under which BMS will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion.

BMS and Celgene merge to create premier innovative biopharma company

The transaction will create a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. With complementary areas of focus, the combined company will operate with global reach and scale, maintaining the speed and agility that is core to each company’s strategic approach.

“Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,” said Giovanni Caforio, Chairman and CEO of BMS. “As a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation. We will also benefit from an expanded early- and late-stage pipeline that includes six expected near-term product launches. Together, our pipeline holds significant promise for patients, allowing us to accelerate new options through a broader range of cutting-edge technologies and discovery platforms.”

Dr Caforio continued: “We are impressed by what Celgene has accomplished for patients, and we look forward to welcoming Celgene employees to BMS. Our new company will continue the strong patient focus that is core to both companies’ missions, creating a shared organization with a goal of discovering, developing and delivering innovative medicines for patients with serious diseases. We are confident we will drive value for shareholders and create opportunities for employees.”

“For more than 30 years, Celgene’s commitment to leading innovation has allowed us to deliver life-changing treatments to patients in areas of high unmet need. Combining with BMS, we are delivering immediate and substantial value to Celgene shareholders and providing them meaningful participation in the long-term growth opportunities created by the combined company,” said Mark Alles, Chairman and CEO of Celgene. “Our employees should be incredibly proud of what we have accomplished together and excited for the opportunities ahead of us as we join with BMS, where we can further advance our mission for patients. We look forward to working with the BMS team as we bring our two companies together.”

Strategic benefits

  • Leading franchises with complementary product portfolios provide enhanced scale and balance. The combination creates:
    • Leading oncology franchises in both solid tumors and hematologic malignancies led by Opdivo and Yervoy as well as Revlimid and Pomalyst
    • A top five immunology and inflammation franchise led by Orencia and Otezla
    • The #1 cardiovascular franchise led by Eliquis.
    • The combined company will have nine products with more than $1 billion in annual sales and significant potential for growth in the core disease areas of oncology, immunology and inflammation and cardiovascular disease.

  • Near-term launch opportunities representing greater than $15 billion in revenue potential. The combined company will have six expected near-term product launches:
    • Two in immunology and inflammation, TYK2 and ozanimod
    • Four in hematology, luspatercept, liso-cel (JCAR017), bb2121 and fedratinib.
    • These launches leverage the combined commercial capabilities of the two companies and will broaden and enhance Bristol-Myers Squibb’s market position with innovative and differentiated products. This is in addition to a significant number of lifecycle management registrational readouts expected in Immuno-Oncology (IO).

  • Early-stage pipeline builds sustainable platform for growth. The combined company will have a deep and diverse early-stage pipeline across solid tumors and hematologic malignancies, immunology and inflammation, cardiovascular disease and fibrotic disease leveraging combined strengths in innovation. The early-stage pipeline includes 50 high potential assets, many with important data readouts in the near-term. With a significantly enhanced early-stage pipeline, BMS will be well positioned for long-term growth and significant value creation.
  • Powerful combined discovery capabilities with world-class expertise in a broad range of modalities. Together, the Company will have expanded innovation capabilities in small molecule design, biologics/synthetic biologics, protein homeostasis, antibody engineering and cell therapy. Furthermore, strong external partnerships provide access to additional modalities.
  • Read More

    Related news

    India says shipments of hydroxychloroquine will resume after US exerts pressure

    India says shipments of hydroxychloroquine will resume after US exerts pressure

    7 Apr 2020

    Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

    Read more 
    Chinese CDMOs legislating for the future

    Chinese CDMOs legislating for the future

    2 Apr 2020

    Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

    Read more 
    FDA orders ranitidine withdrawal due to nitrosamine contamination risk

    FDA orders ranitidine withdrawal due to nitrosamine contamination risk

    2 Apr 2020

    Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

    Read more 
    China focused on meeting international API demand amid pandemic, say officials

    China focused on meeting international API demand amid pandemic, say officials

    1 Apr 2020

    Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

    Read more 
    CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

    CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

    25 Mar 2020

    Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

    Read more 
    2020 - a year for 'big answers' rather than 'big data'

    2020 - a year for 'big answers' rather than 'big data'

    7 Feb 2020

    Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

    Read more 
    Inovio and Beijing Advaccine to advance vaccine against Coronavirus

    Inovio and Beijing Advaccine to advance vaccine against Coronavirus

    30 Jan 2020

    Agreement will facilitate clinical trial translations in China.

    Read more 
    AstraZeneca embarks on $1bn zero carbon strategy

    AstraZeneca embarks on $1bn zero carbon strategy

    24 Jan 2020

    The programme will include the launch of next-generation respiratory inhalers, which will use near-zero Global Warming Potential propellants.

    Read more 
    Diabetes diagnosis - now a matter of sweat and tears?

    Diabetes diagnosis - now a matter of sweat and tears?

    21 Jan 2020

    No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

    Read more 
    2019, the year that got serialization done!

    2019, the year that got serialization done!

    17 Dec 2019

    The past 12 months have been busy as many companies fought to comply with serialization regulations.

    Read more